2 Bay Area biotechs look to raise collective $550 million following deal, trial news

Akero disclosed midstage trial data Monday for its treatment for the fatty liver disease MASH, while BridgeBio announced a deal Sunday to license its heart failure drug to Bayer in Europe.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 4, 2024 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news